UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Clinical manifestations and evaluation of hyperprolactinemia

Author
Peter J Snyder, MD
Section Editor
David S Cooper, MD
Deputy Editor
Kathryn A Martin, MD

INTRODUCTION

The clinical manifestations of hyperprolactinemia are relatively few and usually easy to recognize. Once the presence of prolactin excess is identified, further evaluation to establish the underlying cause is usually straightforward. The clinical manifestations and evaluation of hyperprolactinemia are reviewed here. The causes and treatment of hyperprolactinemia are discussed elsewhere. (See "Causes of hyperprolactinemia" and "Management of hyperprolactinemia".)

CLINICAL PRESENTATION

Hyperprolactinemia causes typical symptoms in premenopausal women and in men but not in postmenopausal women.

Premenopausal women — Hyperprolactinemia in premenopausal women causes hypogonadism, with symptoms that include infertility, oligomenorrhea, or amenorrhea [1,2] and less often galactorrhea. In a retrospective study of 104 patients with hyperprolactinemia ages 30 to 44 years, the most commonly reported symptoms were infertility, headache, and oligomenorrhea in 48, 39, and 29 percent, respectively [3]. Galactorrhea was slightly less common (24 percent).

Menstrual cycle dysfunction — Excluding pregnancy, hyperprolactinemia accounts for approximately 10 to 20 percent of cases of amenorrhea. The mechanism appears to involve inhibition of luteinizing hormone (LH), and perhaps follicle-stimulating hormone (FSH) secretion, via inhibition of the release of gonadotropin-releasing hormone (GnRH). As a result, serum gonadotropin concentrations are normal or low, as in other causes of secondary hypogonadism.

The symptoms of hypogonadism due to hyperprolactinemia in premenopausal women correlate with the magnitude of the hyperprolactinemia. In most laboratories, a serum prolactin concentration above 15 to 20 ng/mL (15 to 20 mcg/L SI units) is considered abnormally high in women of reproductive age.

                    

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Jul 18 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Gómez F, Reyes FI, Faiman C. Nonpuerperal galactorrhea and hyperprolactinemia. Clinical findings, endocrine features and therapeutic responses in 56 cases. Am J Med 1977; 62:648.
  2. Schlechte J, Sherman B, Halmi N, et al. Prolactin-secreting pituitary tumors in amenorrheic women: a comprehensive study. Endocr Rev 1980; 1:295.
  3. Bayrak A, Saadat P, Mor E, et al. Pituitary imaging is indicated for the evaluation of hyperprolactinemia. Fertil Steril 2005; 84:181.
  4. Seppälä M, Ranta T, Hirvonen E. Hyperprolactinaemia and luteal insufficiency. Lancet 1976; 1:229.
  5. Corenblum B, Pairaudeau N, Shewchuk AB. Prolactin hypersecretion and short luteal phase defects. Obstet Gynecol 1976; 47:486.
  6. Biller BM, Baum HB, Rosenthal DI, et al. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992; 75:692.
  7. Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992; 75:698.
  8. Colao A, Di Somma C, Loche S, et al. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 2000; 52:319.
  9. Kleinberg DL, Noel GL, Frantz AG. Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 1977; 296:589.
  10. Carter JN, Tyson JE, Tolis G, et al. Prolactin-screening tumors and hypogonadism in 22 men. N Engl J Med 1978; 299:847.
  11. Segal S, Yaffe H, Laufer N, Ben-David M. Male hyperprolactinemia:effects on fertility. Fertil Steril 1979; 32:556.
  12. Di Somma C, Colao A, Di Sarno A, et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998; 83:807.
  13. Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273.
  14. St-Jean E, Blain F, Comtois R. High prolactin levels may be missed by immunoradiometric assay in patients with macroprolactinomas. Clin Endocrinol (Oxf) 1996; 44:305.
  15. Petakov MS, Damjanović SS, Nikolić-Durović MM, et al. Pituitary adenomas secreting large amounts of prolactin may give false low values in immunoradiometric assays. The hook effect. J Endocrinol Invest 1998; 21:184.
  16. Barkan AL, Chandler WF. Giant pituitary prolactinoma with falsely low serum prolactin: the pitfall of the "high-dose hook effect": case report. Neurosurgery 1998; 42:913.
  17. Kavanagh-Wright L, Smith TP, Gibney J, McKenna TJ. Characterization of macroprolactin and assessment of markers of autoimmunity in macroprolactinaemic patients. Clin Endocrinol (Oxf) 2009; 70:599.
  18. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2006; 65:265.
  19. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clin Ther 2000; 22:1085.